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MaFunctional capacity is a robust predictor of clinical outcomes, and stress testing is used in current practice paradigms to
guide referral to invasive coronary angiography. However, invasive coronary angiography is driven by ongoing symptoms,
as well as risk of adverse outcomes. The limitations of current functional testing-based paradigms might be avoided by
using coronary computed tomographic angiography (CCTA) for exclusion of obstructive coronary artery disease. The
growth of CCTA has been supported by comparative prognostic evidence with CCTA and functional testing, as well as
radiation dose reduction. Use of CCTA for physiological evaluation of coronary lesion-speciﬁc ischemia may facilitate
evaluation of moderate stenoses, designation of the culprit lesion, and prediction of beneﬁt from revascularization. The
potential of CCTA to serve as an effective gatekeeper to invasive coronary angiography will depend, in part, on the
adoption of these new developments, as well as deﬁnition of the beneﬁt of detecting high-risk plaque for guiding the
management of selected patients. (J Am Coll Cardiol 2015;65:2747–56) © 2015 by the American College of Cardiology
Foundation.I nvasive coronary angiography (ICA) is theconcluding step in the diagnostic work-up ofsuspected coronary artery disease (CAD), often
on the basis of results of noninvasive stress testing.
Guideline support of this practice (1) derives from
the prognostic value of functional capacity and
extent of ischemia, as well as data from >15 years
ago evaluating the comparative effectiveness of
direct referral to ICA versus selective referral on
the basis of stress test ﬁndings. These studies sug-
gested cost efﬁciencies from selective referral and
encouraged a noninvasive approach to ICA decision
making (2).m the *Menzies Institute for Medical Research, University of Tasma
rdiovascular Imaging at New York–Presbyterian Hospital and Weill Cornell
rt by a project grant (1080582) from the National Health and Medical Resea
grants from the National Heart, Lung, and Blood Institute (R01 HL111141,
ll as from a generous gift from the Dalio Foundation, to Dr. Min. Dr. M
scular; serves on the medical advisory boards of GE Healthcare and Arin
oKardia, and CardioDx; and holds ownership in MDDX and AutoPlaq. Al
ionships relevant to the contents of this paper to disclose. James Forreste
ten to this manuscript’s audio summary by JACC Editor-in-Chief Dr. Vale
nuscript received April 11, 2015; accepted April 24, 2015.However, functional testing prior to ICA is not
widespread. Possibly as a consequence, 40% of an-
giograms in the NCDR (National Cardiovascular
Database Registry) detect normal coronary arteries
(3). Likewise, less than two-thirds of patients in the
NCDR’s CathPCI program underwent noninvasive
stress testing prior to nonemergent ICA (4). There is
substantial geographic heterogeneity in the use of
functional testing before coronary intervention (5),
with stress testing less likely in women, older pa-
tients, those with impaired mobility, situations of
competing risk (e.g., cancer), and in the hands of
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TABLE 1 Studies of
Kontos et al. (12)
Conti et al. (13)
Bholasingh et al. (15)
Bedetti et al. (16)
Conti et al. (14)
Angio ¼ coronary angiog
NPV ¼ negative predictiv
ABBR EV I A T I ON S
AND ACRONYMS
ACS = acute coronary
syndrome(s)
CAD = coronary artery disease
CCTA = coronary computed
tomographic angiography
CI = conﬁdence interval(s)
CP = chest pain
CT = computed tomography
FFR = fractional ﬂow reserve
FFRCT = fractional ﬂow reserve
derived from CCTA using
computational ﬂuid dynamics
ICA = invasive coronary
angiography
MI = myocardial infarction
MPI = myocardial perfusion
imaging
NPV = negative predictive
value(s)
OR = odds ratio
SE = stress echocardiography
SPECT = single-photon
emission computed
tomography
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2748of percutaneous intervention. The normal
ICA frequency (6) and the frequency of
appropriate ICA use show geographical vari-
ation that is independent of hospital loca-
tion, teaching status, or availability of
revascularization (7). Overuse, underuse, and
misuse may imply poor quality care,
providing justiﬁcation to consider a “gate-
keeper” to the catheterization laboratory.
It was hoped that the recently released
PROMISE (Prospective Multicenter Imaging
Study for Evaluation of Chest Pain) trial
would elucidate the relative roles of CCTA
and functional testing. This study random-
ized >10,000 patients between coronary
computed tomographic angiography (CCTA)
and stress testing (8). A 9% event rate was
anticipated in these patients, who had a 53%
 21% pretest likelihood of obstructive CAD,
and the study was powered for a 20%
reduction to show superiority, and a 10%
margin for noninferiority. However, over a
2-year follow-up, the composite primary
endpoint (death, myocardial infarction [MI],
hospitalization for unstable angina, or major
procedural complication) occurred in only3.3% of the CCTA and only 3.0% of the functional-
testing group (adjusted hazard ratio: 1.04; 95% con-
ﬁdence interval [CI]: 0.83 to 1.29; p ¼ 0.75). Although
these ﬁndings are insufﬁcient to conclude the possi-
bility of either harm or beneﬁt from the use of CCTA, a
particularly salient feature was that although cathe-
terization was performed in more CCTA patients in
the 90 days following noninvasive testing, the like-
lihood of nonsigniﬁcant CAD was signiﬁcantly lower
in the CCTA group (3.4% vs. 4.3%; p ¼ 0.02). Clini-
cians seeking guidance as to whether a CCTA or
functional testing strategy would provide the most
favorable outcomes have been disappointed, with
interpretations ranging from concluding that CCTAFunctional Testing (Stress Echocardiography and SPECT) in A
Modality n
Age
(yrs) Men Design
SPECT 162 56 50 Negative ECG
SPECT 503 62 75 Low-risk, equivocal workup
SE 377 56 58 Negative ECG
SE 552 58 58 Negative ECG and enzymes
New WMA 503 62 75 Negative ECG and enzymes,
normal rest echo
raphy; CAD ¼ coronary artery disease; CP ¼ chest pain; Dipy ¼ dipyridamole; D
e value; PPV ¼ positive predictive value; SE ¼ stress echocardiography; SPECTand functional testing strategies are comparable, to
emphasizing the inconclusive nature due to limited
statistical power (9,10). In this context, there is merit
in reviewing published reports comparing CCTA and
functional testing in diagnosis of CAD.
RESULTS OF FUNCTIONAL TESTING IN
PATIENTS WITH ACUTE CHEST PAIN
Strong evidence supports appropriate use of stress
imaging tests for both diagnostic and prognostic
assessment of CAD (11). Good evidence supports the
use of single-photon emission computed tomography
(SPECT) and stress echocardiography (SE) in patients
presenting acutely with chest pain (CP) (12–16)
(Table 1). Nonetheless, use of functional testing after
presentation with CP may be nonideal—patients have
often been treated with antianginal agents, submax-
imal treadmill tests are common, and complications
are not unusual (17).
Although guidelines recommend the use of stress
testing, recent audits in nearly 400,000 such patients
showed its impact to be modest (3). Patients with
positive tests were only moderately more likely to
show obstructive coronary disease (41% vs. 35%;
p < 0.001; adjusted odds ratio [OR]: 1.28; 95% CI: 1.20
to 1.40). Similarly, in the CathPCI data (4), although
abnormal noninvasive test results improved the
identiﬁcation of individuals with anatomically ob-
structive CAD, the difference in the proportion of
testing among patients with obstructive and non-
obstructive disease was small. Fewer individuals with
nonobstructive CAD—who are at risk of incident MI
and mortality—are recognized with a selective referral
strategy on the basis of functional testing than with
coronary imaging. These ﬁndings evoke concerns that
the current practice paradigm of stress testing fol-
lowed by ICA is ineffective at identifying individuals
who should start treatment for CAD. CCTA is a pro-
mising noninvasive method for identiﬁcation andcute CP Presentations in Studies of >250 Subjects
Stress
Angio
(%)
CAD
Patients
Sensitivity
(%)
Speciﬁcity
(%)
PPV
(%)
NPV
(%)
Rest >70
>50
86
86
76 64 71 70
Rest >50 94 86 83 54 96
Dob >50 25 44 96 42 96
Dipy/dob >50 50 88 100 95 99
Ex >50 94 85 95 81 97
ob ¼ dobutamine; ECG ¼ electrocardiogram; Echo ¼ echocardiogram; Ex ¼ exercise;
¼ single-photon emission computed tomography; WMA ¼ wall motion abnormality.
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2749exclusion of CAD (Table 2) and may provide a diag-
nostic paradigm to curb unnecessary invasive testing.
DIAGNOSTIC PERFORMANCE OF CT
AS THE GATEKEEPER TO ICA
Several hundred single-center evaluations and 3
prospective multicenter trials have evaluated the
diagnostic performance of CCTA for identiﬁcation of
coronary stenoses. CCTA has a demonstrated 94% to
99% sensitivity and 64% to 83% speciﬁcity across a
range of disease prevalence and inclusive of patients
with both acute and stable CP (Figure 1). The 97% to
99% negative predictive value (NPV) of CCTA to
exclude obstructive anatomic stenosis (18–20) means
that a CT-based approach can effectively rule out
anatomic CAD. Whereas stress testing is very effec-
tive for predicting risk, it is unable to exclude CAD,
including severe CAD. A CT approach also has the
attraction of a long “warranty period” (21).
These data extend to “real-world” settings, where—
uniquely among noninvasive tests—the estimated
proportion of patients with obstructive CAD tested
with CCTA was greater than CCTA’s proportion of
overall testing (Table 3). Likewise, in a study of 6,198
patients from 47 centers (22), the relative sensitivity
(94%) and speciﬁcity (38%) of CCTA to identify
anatomically obstructive CAD exceeded the respective
ﬁndings with SPECT (41% and 65%) or SE (49% and
29%). Importantly, the NPV of CCTA (79%) to exclude
obstructive coronary stenosis was superior to SPECT
(33%) and SE (35%). In a randomized trial of angiog-
raphy, SPECT, SE, and cardiac magnetic resonance for
evaluation of suspected CAD, ICA was performed in
about 80% of patients in the noninvasive groups (23),
suggesting that characterization of low risk is insufﬁ-
cient to allay concerns of the clinician and/or patient.
Similar ﬁndings have been reported about the ac-
curacy of CCTA in patients with CP (24–27). On the
basis of these data and assumptions about down-
stream testing and risk, analyses have conﬁrmed
CCTA to be more cost-effective than observation and
stress testing (28).TABLE 2 Studies of CT in Acute CP Presentations in Studies of >100
n
Age
(yrs) Men Design CT Slice
Hoffmann et al. (24) 368 53 61 CP in last 24 h 64
Hollander et al. (25) 519 47 44 TIMI score 0–2 64
Christiaens et al. (26) 167 60 71 CP in last 24 h 64
Litt et al. (27) 677 49 49 TIMI score 0–2 64
Coronary angiography was performed after positive CCTA.
CT ¼ computed tomography; TIMI ¼ Thrombolysis In Myocardial Infarction; other abbDIAGNOSTIC PERFORMANCE OF CT FOR
EVALUATION OF CULPRIT VESSELS AND RISK
One potential advantage of CCTA is the identiﬁcation
and exclusion of speciﬁc coronary lesions that are
targets for coronary revascularization. In a prospec-
tive multicenter, multivendor study (19), CCTA sen-
sitivity and speciﬁcity to identify speciﬁc vessels
were 95% and 77%, respectively. In contrast, SPECT-
myocardial perfusion imaging (MPI) is reportedly
less able to localize stenosis at the vessel level, with
sensitivities of 63% to 80% and speciﬁcities of 70%
to 76%.
CCTA is also useful for the identiﬁcation and
exclusion of high-risk (left main or 3-vessel) CAD in
patients with stable angina, with 95% sensitivity and
83% speciﬁcity (29). The test also excluded ischemic
lesions with NPV of 97% when compared with frac-
tional ﬂow reserve (FFR). However, the positive pre-
dictive values and NPV of CCTA were 53% and 99%,
respectively, suggesting that reliable exclusion of
high-risk CAD was at the cost of overestimation of
high-risk CAD.
Stress testing has also been evaluated for its ability
to detect and exclude high-risk CAD. In a recent
meta-analysis of 32 studies of SPECT (n ¼ 2,310) and
SE (n ¼ 1,403), the sensitivities were 94% and 75%,
with speciﬁcities of 40% and 48% (30), respectively.
Importantly, only 56% of patients with angiograph-
ically proven left main CAD exhibited moderate or
severe ischemia by SPECT, with nearly 1 of 7 in-
dividuals exhibiting no perfusion abnormalities (31).
RELATIVE PROGNOSTIC UTILITY OF
CCTA AND FUNCTIONAL TESTING
Until recently, the prognostic value of SPECT-MPI
was unsurpassed by other noninvasive tests. In a
landmark study of 7,376 patients with normal exer-
cise or adenosine SPECT-MPI from >10 years ago, the
cardiac event rate was only 0.6% per year. This was
linear over time for individuals without known CAD
(32), underpinning the concept of the 18- to 24-monthSubjects
s CT Criteria
Angiography
Criteria
CAD
Patients
Sensitivity
(%)
Speciﬁcity
(%)
PPV
(%)
NPV
(%)
>50 >50 22 100 95 99 99
>50 >50 11 100 100 100 100
>50 >50 28 100 98 90 100
>50 >50 28 100 99 76 100
reviations as in Table 1.
TABLE 3 Diagnostic
Coronary Angiograph
Standard exercise stres
Stress echocardiogram
Stress testing with SPE
Stress testing with CM
CCTA
Values are n (%). *From th
CCTA ¼ coronary compu
Cardiovascular Database R
FIGURE 1 Sensitivity, Speciﬁcity, and Predictive Value of
CCTA in 3 Prospective Multicenter Trials of the Diagnostic
Performance of CCTA
100
80
60
40
20
0
Sensitivity Specificity PPV NPV
ACCURACY (230, 13% prevalence)
EUROPE (360, 68% prevalence)
MEDIC (415, 20-80% risk)
The predictive value of a negative test is uniformly very high.
ACCURACY ¼ Assessment by Coronary Computed Tomographic
Angiography of Individuals Undergoing Invasive Coronary Angi-
ography; CCTA ¼ coronary computed tomographic angiography;
EUROPE ¼ European study (18); MEDIC ¼ Multicenter Evaluation
of Coronary Dual-Source CT angiography in patients with inter-
mediate Risk of Coronary Artery Stenoses; NPV ¼ negative pre-
dictive value; PPV ¼ positive predictive value.
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2750“warranty period” of a normal scan. These data
extend to other methods of stress testing (SE, cardiac
magnetic resonance, and positron emission tomog-
raphy), with the literature supporting the prognostic
importance not only of functional capacity, but also
of the results of imaging (33).
The prognostic utility of CCTA has also been
extensively studied. In the CONFIRM (Coronary CT
Angiography Evaluation for Clinical Outcomes Inter-
national Multicenter) study (34), increasing extent,
severity, and location of CAD predicted adverse out-
comes. CCTA may identify very low-risk individuals—
incremental to clinical scoring systems and CAD risk
factors—and improves prediction, discrimination, and
reclassiﬁcation of these individuals as higher risk in
the presence of CAD (35). Conversely, a large evidence
base supports the benign outcome of patients withoutTesting and Angiographic Findings in Patients Undergoing
y*
Noninvasive Tests
(n ¼ 387,633)
Obstructive CAD
(n ¼ 173,448)
Nonobstructive CAD
(n ¼ 214,185) p Value
s test 37,969 (9.8) 17,016 (9.8) 20,953 (9.8) 0.77
44,829 (11.6) 19,651 (11.3) 25,178 (11.8) <0.001
CT 302,651 (78.1) 134,670 (77.6) 167,981 (78.4) <0.001
R 2926 (0.8) 1331 (0.8) 1595 (0.7) 0.42
8323 (2.1) 5791 (3.3) 2532 (1.2) <0.001
e NCDR database (4).
ted tomographic angiography; CMR ¼ cardiac magnetic resonance; NCDR ¼ National
egistry; other abbreviations as in Table 1.evidence of CAD by CCTA, with annualized event
rates of 0.01% to 0.24% (36). Similar data have been
obtained in patients undergoing CCTA for the evalu-
ation of possible acute coronary syndrome (ACS) (36).
These data highlight the importance of the NPV by
CCTA, not only to rule out obstructive CAD, but also
to effectively rule out future adverse events with a
long-term ($5-year) “warranty period.” CCTA’s ac-
curacy for the exclusion of CAD allows ICA to be
restricted to patients with CT evidence of CAD.
Whereas the assessment of decision making after
the results of functional testing suggests that it is
rarely on the basis of risk (37), this problem may be
more marked with CCTA. In a comparative analysis
of outcomes after CT and stress testing in a large
Medicare population, the provision of anatomic data
was associated with an increased likelihood of sub-
sequent cardiac catheterization, percutaneous coro-
nary intervention, and coronary artery bypass graft
surgery with CCTA compared with SPECT, and
consequently with higher costs (38). CCTA use was
associated with a lower likelihood of hospitalization
for acute MI (0.19% vs. 0.43%; adjusted OR: 0.60; 95%
CI: 0.37 to 0.98; p ¼ 0.04), but no difference in overall
mortality.
IDENTIFICATION OF INDIVIDUALS WHO
WILL AND WILL NOT BENEFIT FROM
CORONARY REVASCULARIZATION
Coronary revascularization decisions should not be
solely on the basis of anatomic stenosis (39,40).
Former comparisons between anatomic (ICA) and
functional approaches showed that interventions
were twice as likely once the coronary anatomy was
known (2). In contrast, failure to identify perfusion or
wall motion abnormalities, preserved exercise ca-
pacity, and lack of ST-segment abnormality are all
functional testing results pointing to low risk. In
several large observational studies, revascularization
was associated with more favorable outcomes in in-
dividuals with a signiﬁcant amount of ischemia
(>12.5%), and with better outcomes in individuals
with limited ischemia with medical therapy (41).
In contrast, moderate (40% to 70%) stenoses
correlate poorly with the presence and degree of
impaired coronary vasodilator reserve (42). Approxi-
mately 20% of patients with apparently signiﬁcant
stenoses are identiﬁed as having normal FFR, and
13% of those thought to have nonsigniﬁcant stenoses
have abnormal ﬂow reserve (43). The absence of this
functional information is a potential limitation for
CCTA and argues for the use of ischemia-based eval-
uations to guide revascularization decisions.
FIGURE 3 Derivation of FFRCT From Typical CT Acquisition
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2751Nonetheless, selective referral of patients for ICA
on the basis of CCTA ﬁndings may improve the
likelihood of beneﬁt versus harm. In 15,223 patients
without known CAD followed for 2.1 years, patients
who underwent revascularization plus medical ther-
apy experienced signiﬁcantly lower rates of mor-
tality than those treated with medical therapy alone
(2.3% vs. 5.3%; p < 0.01), a difference that became
more marked with increasing numbers of vessels
with obstructive CAD (44) (Figure 2). The observation
that ICA performance for CCTA-identiﬁed obstruc-
tive CAD imparted a 40% lower rate of mortality
in a 2-year follow-up supports these ﬁndings (45).
In contrast, individuals undergoing ICA without
obstructive CAD by CCTA showed a >2-fold increased
risk of mortality. Thus, CCTA may identify CAD
burden thresholds that may guide revascularization
decisions.
DEFINITION OF THE ISCHEMIA-CAUSING
CORONARY ARTERY LESION
A robust body of evidence exists for the use of FFR to
guide decisions regarding coronary revascularization
of individual stenoses. FFR guidance has been asso-
ciated with a 28% lower event rate compared with
anatomic stenosis-guided PCI alone (46).
The recent application of computational ﬂuid dy-
namics to standard CCTA acquisitions has enabled
calculation of fractional ﬂow reserve derived fromFIGURE 2 Use of CCTA to Identify Angiographic Thresholds
for CAD for Which ICA Is Versus Is Not Indicated (n ¼ 15,223)
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These data on observed mortality rates for patients with
obstructive coronary artery disease (CAD) undergoing medical
therapy (medical Tx) or revascularization (revasc) emphasize the
importance of characterizing high-risk (survival beneﬁt with
revascularization) versus non–high-risk CAD (lower mortality
rates when treated with medical therapy alone). Modiﬁed with
permission from Min et al. (44). CCTA ¼ coronary computed
tomographic angiography.CCTA using computational ﬂuid dynamics (FFRCT) at
any point in the coronary vascular bed (Figure 3),
without the need for additional imaging, modiﬁcation
of image acquisition protocols, additional radiation
doses, or medication administration. A recent meta-
analysis of the 3 prospective, multicenter FFRCT tri-
als that used invasive FFR as the reference standard
(DISCOVER-FLOW [Diagnosis of Ischemia-Causing
Stenoses Obtained via Noninvasive Fractional Flow
Reserve], DeFACTO [Determination of Fractional
Flow Reserve by Anatomic Computed Tomographic
Angiography], and NXT [Analysis of Coronary Blood
Flow Using CT Angiography: Next Steps]) (47)
compiled ﬁndings in 609 patients (1,050 vessels). At
the patient level, the pooled sensitivity (89%; range:
85% to 93%) and speciﬁcity (71%; range: 65% to 75%)
were similar to CTA, although the area under the
summary receiver-operating characteristic curves for
FFRCT (0.89) was greater than that for CTA (0.74).
Sensitivity (70%; range: 65% to 75%) at the vessel
level was lower, and speciﬁcity (90%; range: 85% toFFRCT
1.00
0.90
0.80
0.70
Simulation of HeartFlow’s FFRct Technology
Simulation of coronary pressure and flow
There are no requirements for modiﬁcation of imaging protocols, additional image
acquisition, additional radiation, or administration of adenosine. FFRCT may be selected at
any point in the coronary tree (Online Video 1). CT ¼ computed tomography; FFR ¼
fractional ﬂow reserve.
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275293%) was higher; thus, FFRCT may reduce the number
of false-positive studies that identify anatomical
CAD of no hemodynamic signiﬁcance. FFRCT similarly
allows identiﬁcation of patients and particular coro-
nary artery lesions that may beneﬁt from revas-
cularization. By “virtual” stenting methods, wherein
revascularization was computationally modeled by
computational ﬂuid dynamics techniques, Kim et al.
(48) observed a 100% speciﬁcity and 96% sensitivity
for pre- and post-percutaneous coronary intervention
FFR values by FFRCT. Thus, CCTA combined with FFR
may optimize the prediction of the therapeutic
beneﬁt of intervention.
ANATOMIC-PHYSIOLOGICAL DISCORDANCE
In the management approach to negative and positive
test results, the presence or absence of anatomic CAD
does not equate to the presence or absence of
ischemia.
“INCIDENTAL” CAD. An emphasis on detection of
anatomic CAD may risk the attribution of atypical
symptoms to “incidental” CAD. Coronary disease is
highly prevalent; approximately 18% of men and 11%
of women >65 years of age have signiﬁcant disease,
increasing to 19% and 16%, respectively, at >75 years
(49). In the absence of corroborative functional
testing, detection of signiﬁcant anatomic diseaseFIGURE 4 Prognostic Implications of Functional Testing in Patients
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In 457 patients with chest pain (CP) (245 men; 56  10 years) with pos
survival was approximately 75%, compared with 90% in patients with a n
(52). CAD ¼ coronary artery disease.does not necessarily incriminate CAD as the source of
the patient’s symptoms.
VASOACTIVE ANGINA. The absence of anatomic cor-
onary stenoses does not signify the lack of myocardial
ischemia due to abnormal metabolism or vasoactivity.
Functional coronary disease may be epicardial or
microvascular in origin (50). Similarly, microvascular
dysfunction may be due to hypertension, cardiomy-
opathy, inﬁltrative disease, or be idiopathic.
Patients with positive functional tests in the
absence of anatomic coronary disease do not neces-
sarily have a benign prognosis (Figure 4), and those
with an abnormal functional test result are particularly
at risk (51). In women with normal coronary arteries
having CP, the probability of CP hospitalization is
about one-half that for obstructive coronary disease,
and there is a high prevalence of functional disability
and ongoing symptoms (including a 45% prevalence of
typical angina—not signiﬁcantly different fromwomen
with obstructive coronary disease) (Figure 5) (52).
Indeed, at least a subgroup seems likely to truly have
ischemia, with evidence of abnormal myocardial
metabolism obtained by magnetic resonance spec-
troscopy. The 3-year event rate in this group is
approximately 40%, no different from patients with
structural coronary disease, and substantially more
frequent than those with no coronary disease
and normal spectroscopy (53). The subendocardialWith CP and No Anatomic CAD
Negative DET (96.4%)
Positive DET (89.8%)
Log-rank 4.05, P = 0.044
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itive high-dose dipyridamole echocardiography (DET), the 10-year
egative test, with a similar but smaller difference for cardiac mortality
FIGURE 5 Functional Disability and Angina in Women
With CP
80%
70
60
50
40
30
20
10
0
Typical Angina Functional Disability
Nonobstructive 1VD
2VD 3VD
Typical angina was present in 35% to 45% of women with
nonobstructive and 1- to 3-vessel coronary artery disease.
Functional disability (deﬁned by a Duke activity status index#4.7
metabolic equivalents) was present in one-half of these patients,
even in the absence of obstructive coronary artery disease (53).
CP ¼ chest pain; VD ¼ vein disease.
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2753ischemia responsible for this presentation is identiﬁ-
able by stress perfusion magnetic resonance.
NEGATIVE CT CORONARY ANGIOGRAM AND CARDIAC
SYMPTOMS. Negative CCTA does not exclude a
number of potential noncoronary cardiac diseases.
Whereas CCTA may recognize certain anatomic eti-
ologies of symptoms, such as CP or shortness of
breath—including hypertrophic cardiomyopathy,
aortic stenosis, or subaortic membranes—it is gener-
ally poor for evaluating more physiological causes,
such as mitral regurgitation, diastolic dysfunction, or
pulmonary hypertension.
Thus, despite the high NPV of CCTA for exclusion
of anatomic CAD, functional testing confers incre-
mental beneﬁts in relation to clinical decision making
(Figure 4).
DETECTION OF HIGH-RISK PLAQUE
Beyond the binary dichotomization of CAD versus no
CAD, CCTA also enables visualization of mild non-
obstructive CAD that can help identify individuals at
risk of incident MI or cardiac death. For these subjects
(>85% of individuals experiencing MI), identiﬁcation
of subclinical CAD offers the opportunity to stratify
risk of future mortality. Indeed, those individuals
with <50% stenosis, but mild CAD in all 3-vessel
territories, experience a >6-fold increased risk of
death in a 3-year period. These ﬁndings advocate for anoninvasive approach to risk stratiﬁcation, beyond
measures of obstructive CAD or ischemia.
Comprehensive plaque characterization includes
evaluation of plaque burden, plaque composition
(including necrotic lipid core), arterial remodeling,
inﬂammation, and thickness of the plaque surface cap.
Characterization of speciﬁc atherosclerotic plaque
features by CCTA might enhance risk stratiﬁcation.
Over 27 months of follow-up, Motoyama et al. (54)
reported that baseline scans showing necrotic intra-
plaque cores and positive remodeling showed a 22%
incidence of ACS, which is much greater than scans
with either (3.7%), or neither ﬁnding (0.5%). Culprit
plaques implicated in ACS demonstrated a 2-fold
higher plaque volume. These data are consistent
with a study of non–ST-segment elevation MI patients
who underwent a concurrent CCTA at the time of ACS
presentation (55). At a 16-month follow-up, 23 of 312
individuals who experienced a subsequent event had
higher baseline CT total nonobstructive plaque vol-
ume, largely due to noncalciﬁed plaque volume,
although low-attenuation plaque was not speciﬁcally
measured. Future studies are necessary to deﬁne
whether these ﬁndings can further stratify referral
patterns to ICA (or decisions for revascularization).
RADIATION SAFETY
The effective biological radiation dose conferred
by CCTA is an important consideration. The high
radiation doses associated with ﬁrst-generation
64-detector-row scanners were generally obtained
without radiation dose-reduction methods. By the
end of the last decade, doses were reduced to 12 mSv,
but with ongoing high heterogeneity (56). Over
the past few years, electrocardiogram modulation,
prospective triggering, and iterative reconstruction—
as well as body mass index and heart-rate–adjusted
tube voltage and current—have resulted in signiﬁ-
cantly lower doses. A temporal reduction in radia-
tion dose that is inversely proportional to the newly
introduced technologies and strategies has been
observed in numerous prospective multicenter
trials. For example, among 11,901 patients imaged
from 15 centers in the Advanced Cardiovascular
Imaging Consortium, CCTA averaged more than
20 mSv of radiation, which was signiﬁcantly lowered
(>50%) with a radiation dose-reduction quality
improvement program (57). More recent studies
with individualized doses using multiple dose-
reduction methods have obtained scans with CCTA
doses in the 1-mSv range (58), with select individuals
receiving doses as low as in screening mammography
(0.06 mSv).
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CAD ¼ coronary artery disease; CCTA ¼ coronary computed tomographic angiography; CT¼ computed tomography; FFR ¼ fractional ﬂow reserve.
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Results from future prospective multicenter studies
will be needed to justify CCTA’s contribution to se-
lection of patients with suspected CAD for ICA.
The CREDENCE (Computed Tomographic Evaluation
of Atherosclerotic Determinants of Myocardial
Ischemia) trial (NCT02173275) (59) is a diagnostic
performance study directly testing CCTA against
stress testing, using invasive FFR as a reference
standard. CREDENCE will develop and validate an
integrated score to capture the totality of information
from each test type that may be useful for diagnosis
of hemodynamically signiﬁcant CAD. The CCTA score
will combine measures of stenosis severity, plaque
burden and location, composition, remodeling, and
FFRCT. The stress MPI score will include measures of
perfusion, ventricular function, and high-risk ﬁnd-
ings (e.g., transient ischemic dilation). Finally, the
CONSERVE (Coronary Computed Tomographic Angi-
ography for Selective Cardiac Catheterization) trial
(NCT01810198) (60) is directly testing the concept of
CCTA as a gatekeeper to ICA. In this randomized
controlled trial, patients with an American College ofCardiology/American Heart Association guideline–
supported indication for nonemergent ICA will un-
dergo direct ICA as intended or selective ICA
depending on initial CCTA results. Enrollment has
completed and 1-year results are pending.
At present, it seems prudent to individualize this
decision to each patient’s circumstances. In addition
to the merits of early investigation and short emer-
gency room stays, the high NPV of a CCTA-guided
approach is most beneﬁcial when the probability of
CAD is low. In intermediate-risk patients who have
not started on statins and other risk-modifying drugs,
the selection of CCTA may provide evidence of sub-
clinical CAD that cannot be shown by functional
testing. However, a positive CCTA raises questions
about ﬂow-limiting disease. In the absence of FFRCT,
a positive CCTA should evoke considerations of other
investigations addressing whether the symptoms are
due to CAD (Central Illustration), whether stenosis is
ﬂow-limiting, and whether there is prognostically
important CAD, especially if revascularization is
being considered. Functional testing imparts the in-
formation necessary to resolve these questions and
may uncover other causes of CP. Radiation exposure
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2755considerations may favor SE in younger patients,
especially if repeated testing is considered in young
women. Likewise, suspicion of left ventricular or
valvular disease favors echocardiography.
CCTA has the potential to serve as an effective
gatekeeper to curb unnecessary ICA. However,
there is no deﬁnitive evidence to favor either a
CCTA-guided or a stress testing–guided approach for
evaluation of acute CP (Table 3). The difference
between these approaches is likely smaller than
the variation arising from the heterogeneity of the
patients under study. The PROMISE trial results areequivocal (7), and it seems improbable that the
strength of evidence will be deemed sufﬁcient to
justify a Class I indication for CCTA, although
upgrading to a Class IIA indication would reﬂect
the conclusion that consideration of this test is
reasonable.
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